December 14, 2017
Gilead Sciences Announces That John C. Martin, PhD Will Transition From Executive Chairman to Chairman of the Board of Directors
FOSTER CITY, Calif.--(BUSINESS WIRE)--Dec. 14, 2017--
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Executive
Chairman John Martin, PhD will transition from his current role of
Executive Chairman to Chairman of the Board of Directors effective March
9, 2018. Dr. Martin was named Executive Chairman on March 10, 2016, when
he was succeeded as CEO by John Milligan, PhD. Dr. Martin served as CEO
of Gilead from 1996 to 2016, having joined the company in 1990 as the
Vice President of Research and Development. During his time as CEO, he
built the company’s portfolio to 24 marketed products with annual
revenues of more than $32 billion.
“John's scientific and business leadership has been notable for the
development of Gilead’s portfolio of HIV and viral hepatitis medicines
and commitment to worldwide access for patients. We are all grateful
that he will continue to help guide the company as Chairman of the
Board,” said Dr. Milligan, President and CEO of Gilead.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops
and commercializes innovative therapeutics in areas of unmet medical
need. Gilead’s mission is to advance the care of patients suffering from
life-threatening diseases. Gilead has operations in more than 30
countries worldwide, with headquarters in Foster City, California.
For more information on Gilead Sciences, please visit the company’s
website at www.gilead.com,
follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs
at 1-800-GILEAD-5 or 1-650-574-3000.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171214006171/en/
Source: Gilead Sciences, Inc.
Gilead Sciences, Inc.
Sung Lee, 650-524-7792